DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice.
ESAT-6 is a protein produced by virulent Mycobacterium tuberculosis but absent in Mycobacterium bovis bacillus Calmette-Guerin (BCG) and is considered as a promising vaccine subunit against tuberculosis. The protective efficacy of a new strategy based on the combination of DNA vaccine encoding ESAT-6 (DNA-E6) and BCG immunization was investigated in the present study. BALB/c mice were immunized with DNA-E6, BCG, DNA-E6 plus BCG, vector plus BCG or vector alone. Three weeks after the last immunization, antigen-specific interferon (IFN)-gamma secreted upon stimulation with BCG-PPD or ESAT-6 protein by splenocytes of the different groups was determined by an ELISA. The immunized mice were challenged intravenously with low-dose virulent M. tuberculosis H37Rv and bacterial load of the infected mice was measured in the spleen and lung 6 weeks later. Pathological changes in the lung were observed by haematoxylin-eosin (HE) or acid-fast staining. Our study demonstrated that ESAT-6-specific IFN-gamma was improved in mice vaccinated with DNA-E6 plus BCG, compared with those mice immunized with BCG alone. The combination of DNA-E6 and BCG resulted in the maximum reduction in bacterial load in both the lung and spleen, and only slight pathological changes were detected in the lung. These results suggested that the combination of DNA-E6 and BCG vaccination could be a better strategy against M. tuberculosis infections in human.